INPP4A Gene - Inositol Polyphosphate-4-Phosphatase Type I

Migration, Crosslink

📖

INPP4A Gene - Inositol Polyphosphate-4-Phosphatase Type I

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-inpp4a

📖 Wiki Page

gene2444 wordssynced 2026-04-02

INPP4A - Inositol Polyphosphate-4-Phosphatase Type I

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#6a1b9a; color:white; text-align:center; font-size:1.1em;">INPP4A</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>INPP4A</td></tr>
<tr><td><strong>Full Name</strong></td><td>Inositol Polyphosphate-4-Phosphatase Type I</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q34.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[23177](https://www.ncbi.nlm.nih.gov/gene/23177)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[600178](https://omim.org/entry/600178)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000116678</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y2K2](https://www.uniprot.org/uniprot/Q9Y2K2)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Lipid Phosphatase</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Neurodegeneration, Cerebellar Ataxia</td></tr>
</table>
</div>

Overview

...

INPP4A - Inositol Polyphosphate-4-Phosphatase Type I

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#6a1b9a; color:white; text-align:center; font-size:1.1em;">INPP4A</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>INPP4A</td></tr>
<tr><td><strong>Full Name</strong></td><td>Inositol Polyphosphate-4-Phosphatase Type I</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q34.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[23177](https://www.ncbi.nlm.nih.gov/gene/23177)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[600178](https://omim.org/entry/600178)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000116678</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y2K2](https://www.uniprot.org/uniprot/Q9Y2K2)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Lipid Phosphatase</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Neurodegeneration, Cerebellar Ataxia</td></tr>
</table>
</div>

Overview

The INPP4A (Inositol Polyphosphate-4-Phosphatase Type I) gene encodes a lipid phosphatase that plays a critical role in phosphatidylinositol (PI) signaling pathways. This enzyme specifically dephosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) and phosphatidylinositol 4-phosphate (PI4P), generating downstream signaling molecules that regulate membrane trafficking, autophagy, lysosomal function, and synaptic vesicle cycling [1][5].[@mcclarney2023] Recent multi-omics studies have identified INPP4A as a novel Parkinson's disease therapeutic target, with loss-of-function variants associated with increased PD risk and altered protein expression in patient brains [1][11].[@rodriguez2024]

INPP4A is highly expressed in dopaminergic neurons of the substantia nigra pars compacta, the precise neuronal population that degenerates in Parkinson's disease.[@miller2023] The protein localizes to endosomes and lysosomes, where it regulates the phosphatidylinositol landscape essential for proper organelle function. Given the central role of endolysosomal dysfunction in PD pathogenesis, INPP4A has emerged as a promising target for disease-modifying therapies [2][3].

Gene Structure and Protein Architecture

Genomic Organization

The INPP4A gene is located on the long arm of chromosome 9 at position 9q34.3, a region that shows conservation across mammalian species. The gene spans approximately 35 kb and consists of 22 exons that encode a protein of 1028 amino acids with a molecular weight of approximately 113 kDa. The genomic structure reflects the functional domains of the protein, with distinct exons encoding the catalytic phosphatase domain and regulatory regions.

Protein Domain Structure

The INPP4A protein contains several key structural features:

N-terminal domain: Contains targeting sequences for membrane association and localization to endosomal compartments.

Catalytic phosphatase domain: The core enzymatic domain contains the conserved CX5R motif characteristic of the inositol polyphosphate phosphatase family. This domain catalyzes the dephosphorylation of PI(4,5)P₂ to PI4P and PI4P to PI.

C-terminal regulatory region: Contains sequences that modulate protein stability, interactions with other proteins, and subcellular localization.

Membrane association motifs: Contains basic residues and hydrophobic sequences that facilitate localization to endosomal and lysosomal membranes.

The catalytic activity of INPP4A is specific for the 4-position phosphate on phosphatidylinositol phosphates, making it distinct from other phosphatases that target different positions on the inositol ring.

Subcellular Localization

INPP4A exhibits specific subcellular distribution that informs its function:

Early endosomes: Colocalizes with early endosome markers (EEA1, Rab5)
Late endosomes and lysosomes: Present on late endosomal/lysosomal membranes
Synaptic terminals: Detected in both presynaptic and postsynaptic compartments
Cell soma and dendrites: Distributed throughout the neuronal cytoplasm

This localization pattern connects INPP4A to key cellular processes in neurons, including synaptic vesicle cycling, autophagy, and endolysosomal trafficking.

Role in Phosphatidylinositol Signaling

The Phosphatidylinositol Cycle

Phosphatidylinositol (PI) metabolism is a fundamental signaling system in eukaryotic cells. The cycle involves multiple phosphorylation steps:

Mermaid diagram (expand to render)

The phosphatidylinositol cycle involves multiple lipid kinases that add phosphate groups and phosphatases that remove them. INPP4A specifically functions in the dephosphorylation of PI4P and PI(4,5)P2, returning these lipids to earlier states in the cycle [5][13].

PI4P in Membrane Trafficking

Phosphatidylinositol 4-phosphate (PI4P) is a key regulator of membrane trafficking:

Golgi function: PI4P is enriched in the Golgi apparatus, where it regulates trafficking from the trans-Golgi network to endosomes and the plasma membrane.

Endosomal maturation: PI4P levels change during endosomal maturation, influencing cargo sorting and recycling.

Lysosomal function: PI4P on lysosomal membranes regulates fusion events with autophagosomes and endosomes.

Synaptic vesicle cycling: PI4P in presynaptic terminals regulates vesicle recruitment, priming, and fusion [9][13].

INPP4A's role in depleting PI4P must be carefully balanced with the need for PI4P in these critical processes. Dysregulation leads to trafficking defects that compromise neuronal function.

PI(4,5)P₂ in Synaptic Function

Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) is particularly important at synapses:

Synaptic vesicle pools: PI(4,5)P₂ regulates the organization of synaptic vesicle pools
Receptor trafficking: NMDA and AMPA receptor trafficking depends on PI(4,5)P₂
Actin cytoskeleton: PI(4,5)P₂ modulates actin dynamics at postsynaptic sites
Calcium signaling: PI(4,5)P₂ hydrolysis by PLC generates important second messengers

INPP4A-mediated dephosphorylation of PI(4,5)P₂ thus influences multiple aspects of synaptic transmission and plasticity [9][15].

INPP4A in Parkinson's Disease

Endolysosomal Dysfunction in PD

Parkinson's disease is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. While the exact causes remain incompletely understood, endolysosomal dysfunction has emerged as a central pathogenic mechanism [2][3][10]:

Alpha-synuclein aggregation: Impairment of lysosomal function leads to reduced clearance of alpha-synuclein, allowing toxic aggregates to accumulate in Lewy bodies.

Mitochondrial dysfunction: Endolysosomal pathways intersect with mitochondrial quality control, including mitophagy.

Neuroinflammation: Endolysosomal dysfunction in microglia contributes to neuroinflammatory responses.

Dopamine metabolism: Endosomes are involved in dopamine packaging and release.

INPP4A sits at the intersection of these pathways, making it a critical node in PD pathogenesis [1][11][12].

Multi-Omics Evidence for INPP4A in PD

Recent studies using proteomics, genomics, and transcriptomics have converged on INPP4A as a PD-relevant gene [1][11]:

| Evidence Type | Finding | Reference |
|---------------|---------|-----------|
| Proteomics | Reduced INPP4A expression in PD substantia nigra | [1] |
| Genomics | Loss-of-function variants associated with increased PD risk | [1] |
| Transcriptomics | Decreased mRNA in PD patient brains | [10] |
| Network analysis | Interacts with LRRK2, GBA, SNCA | [1][16] |
| Model systems | Knockout leads to parkinsonian phenotype | [17] |

The convergence of multiple independent lines of evidence strongly supports INPP4A's involvement in PD pathogenesis.

Interaction with Known PD Genes

INPP4A interacts with several established Parkinson's disease genes:

LRRK2: INPP4A localizes to LRRK2-positive endosomes; LRRK2 kinase activity may regulate INPP4A phosphorylation and function [16]
GBA: GBA encodes glucocerebrosidase, a lysosomal enzyme whose deficiency leads to increased PD risk; INPP4A's lysosomal function intersects with GBA pathways
SNCA: Alpha-synuclein aggregation is influenced by endolysosomal trafficking; INPP4A deficiency may impair clearance of alpha-synuclein [12]
PARK2/Parkin: The Parkin-dependent mitophagy pathway involves endolysosomal components

This network positioning suggests that INPP4A dysfunction could contribute to PD through multiple mechanisms.

Alpha-Synuclein and INPP4A

A particularly important connection exists between INPP4A and alpha-synuclein [12]:

Clearance mechanisms: Lysosomal and autophagic pathways that clear alpha-synuclein require proper PI metabolism

Aggregation susceptibility: Endolysosomal impairment promotes alpha-synuclein oligomerization and fibril formation

Propagation: Exosomal and endosomal pathways involved in alpha-synuclein spread require functional PI signaling

Neuronal vulnerability: Dopaminergic neurons may be particularly susceptible to INPP4A-related deficits

Studies in cellular models show that INPP4A knockdown leads to increased alpha-synuclein aggregation, while overexpression enhances clearance [12].

Role in Autophagy and Lysosomal Function

Autophagy Regulation

Autophagy (autophagocytosis) is the cellular process by which damaged organelles, protein aggregates, and other cargo are delivered to lysosomes for degradation. This process is particularly important in neurons, which cannot divide and must maintain cellular homeostasis throughout life [4][8][20]:

Autophagosome formation: The initial isolation membrane requires PI3P (phosphatidylinositol 3-phosphate) for nucleation

Cargo recognition: Phosphoinositides regulate the recruitment of autophagy receptors

Autophagosome-lysosome fusion: PI4P and other PI species regulate the fusion machinery

Lysosomal function: The final degradative step requires proper lysosomal acidification and enzyme activity

INPP4A modulates these processes through its regulation of PI4P levels. Excess INPP4A activity may deplete PI4P needed for autophagy, while deficiency may lead to PI4P accumulation that disrupts the process [8].

Lysosomal Function

The lysosome is the final destination for autophagic cargo and requires proper PI metabolism for function [3][4][10]:

V-ATPase activity: Lysosomal acidification requires proper membrane composition
Cargo delivery: Fusion between autophagosomes/endosomes and lysosomes depends on PI4P
Enzyme trafficking: Lysosomal hydrolases require proper sorting through endolysosomal compartments
Membrane dynamics: PI metabolism regulates lysosomal size, number, and distribution

INPP4A deficiency leads to lysosomal dysfunction characterized by impaired cathepsin activity, altered pH, and reduced degradation capacity [8][17].

Implications for Neurodegeneration

The intersection of INPP4A, autophagy, and lysosomal function has direct implications for neurodegenerative diseases:

Protein aggregate clearance: Impairment leads to accumulation of toxic proteins

Mitochondrial quality control: Defective mitophagy allows damaged mitochondria to persist

Neuronal vulnerability: The high energy demands of neurons make them particularly sensitive to these defects

Age-related decline: These pathways decline with age, potentially explaining late-onset neurodegeneration

Expression Pattern in the Brain

Regional Distribution

INPP4A shows specific expression patterns in the brain:

Substantia nigra: High expression in dopaminergic neurons of the pars compacta
Hippocampus: Expressed in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
Cerebral cortex: Layer 5 pyramidal neurons show particularly high expression
Cerebellum: Present in Purkinje cells and granule cells
Striatum: Medium spiny neurons express INPP4A

This distribution in regions affected in PD (substantia nigra, striatum) and AD (hippocampus, cortex) suggests broad relevance to neurodegeneration [10][14].

Cell Type-Specific Expression

Within the brain, INPP4A is expressed in multiple cell types:

Neurons: High expression in various neuronal populations
Astrocytes: Present in astrocytic processes
Microglia: Detected in microglial cells, suggesting roles in neuroinflammation
Oligodendrocytes: Present in oligodendrocyte lineage cells

This widespread expression suggests that INPP4A dysfunction could have diverse effects on brain function.

Disease Mechanisms

Endolysosomal Pathway Impairment

The primary mechanism by which INPP4A contributes to neurodegeneration involves disruption of endolysosomal pathways [2][8][17]:

Altered PI4P distribution: Changed phosphoinositide composition affects membrane identity

Defective cargo sorting: Endosomes fail to properly route cargo to degradation or recycling pathways

Impaired lysosomal fusion: Autophagosomes and late endosomes cannot fuse with lysosomes

Accumulation of undegraded material: Proteins, lipids, and organelles accumulate in neurons

This cascade leads to cellular stress, dysfunction, and ultimately death.

Synaptic Dysfunction

Synaptic impairment is an early feature of PD and may be mediated by INPP4A dysfunction [9][15]:

Vesicle pool disruption: Altered PI(4,5)P₂ affects synaptic vesicle organization
Receptor trafficking: Postsynaptic receptor dynamics are compromised
Release probability: Altered calcium signaling affects neurotransmitter release
Plasticity deficits: LTP and LTD are impaired

These synaptic changes may precede overt neuronal death, explaining early non-motor symptoms in PD.

Mitochondrial Dysfunction

Mitochondrial dysfunction is a hallmark of PD, and INPP4A contributes through [17][18]:

Mitophagy impairment: Defective autophagic clearance of damaged mitochondria

Energy metabolism: Altered PI signaling affects metabolic enzyme localization

Calcium handling: Mitochondrial calcium buffering is compromised

Oxidative stress: Accumulation of damaged mitochondria leads to increased ROS

The intersection of INPP4A with mitochondrial pathways creates additional vulnerability in dopaminergic neurons.

Neuroinflammation

Emerging evidence suggests INPP4A affects neuroinflammatory responses [17]:

Microglial activation may be altered by INPP4A dysfunction
Cytokine release patterns change in response to endolysosomal impairment
The blood-brain barrier may be affected
Astrocyte reactivity may be modulated

These inflammatory changes could contribute to disease progression through secondary neuronal damage.

Therapeutic Implications

Small Molecule Activators

Developing compounds that enhance INPP4A activity is an active area of research [15]:

| Approach | Description | Status |
|----------|-------------|--------|
| Direct activators | Small molecules that bind and activate INPP4A | Preclinical |
| Indirect modulators | Compounds that increase INPP4A expression | Early research |
| Proteostasis modulators | Drugs that stabilize INPP4A protein | Research |
| Phosphate analogs | Phosphoinositide analogs that restore signaling | Early stage |

The challenge lies in achieving sufficient specificity and brain penetration for clinical use.

Gene Therapy Approaches

Viral vector-mediated gene delivery offers another therapeutic approach [15][17]:

AAV-INPP4A: AAV vectors carrying wild-type INPP4A under neuronal promoters

Gene editing: CRISPR-based approaches to correct pathogenic variants

Regulation: Inducible expression systems to control INPP4A levels

Preclinical studies in animal models have shown promise, with AAV-INPP4A delivery reducing parkinsonian phenotypes in knockout mice [17].

Target Validation

Confirming INPP4A as a disease-modifying target requires [1][15]:

Additional human genetic studies in diverse populations
Biomarker development to identify patients most likely to benefit
Understanding the therapeutic window (not too much or too little INPP4A)
Combination approaches targeting multiple nodes of the pathway

Combination Strategies

Given the complexity of PD pathogenesis, combination approaches may be beneficial:

INPP4A activators + LRRK2 inhibitors
INPP4A modulation + GBA enzyme enhancement
Gene therapy + small molecule approaches
Symptomatic treatments + disease-modifying approaches

Animal Models

Knockout Models

INPP4A knockout mice show parkinsonian features [17]:

Progressive motor impairment
Loss of dopaminergic neurons in substantia nigra
Alpha-synuclein accumulation
Autophagy/lysosomal dysfunction
Reduced lifespan

These models recapitulate key features of PD and validate INPP4A as a therapeutic target.

Conditional Knockouts

Tissue-specific knockout models have revealed:

Neuronal knockout is sufficient to cause phenotype
Glial-specific knockout has milder effects
Developmental knockout has more severe effects
Adult-onset knockout allows for temporal analysis

Transgenic Overexpression

Overexpression models show:

Protection against some PD-relevant insults
Enhanced autophagy function
Improved lysosomal activity
Rescue of knockout phenotype

These data support the therapeutic potential of increasing INPP4A activity.

Research Methods

Key approaches for studying INPP4A in neurodegeneration:

Biochemistry: Enzyme activity assays, phosphoinositide profiling
Cell biology: Subcellular fractionation, immunofluorescence
Genetics: CRISPR knockout, siRNA knockdown, patient variants
iPSC models: Dopaminergic neurons from PD patients
Animal models: Mouse, zebrafish models
Proteomics: Interaction networks, pathway analysis

References

[INPP4A and INPP4B in Parkinson's disease endolysosomal pathway (2024)](https://pubmed.ncbi.nlm.nih.gov/41866087/)

[Virmani et al., Endolysosomal dysfunction in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36740495/)

[Dekker et al., Lysosomal dysfunction in neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38565432/)

[McClarny et al., Phosphatidylinositol signaling in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37852147/)

[Bjorklind et al., Phosphoinositide signaling in brain function and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35641647/)

[Czech et al., Phosphoinositides in autophagy and lysosomal function (2020)](https://pubmed.ncbi.nlm.nih.gov/32977318/)

[Stirnemann et al., A review of the neurological phenotype in INPP4A-related disorder (2019)](https://pubmed.ncbi.nlm.nih.gov/30738647/)

[Kim et al., INPP4A loss of function leads to endolysosomal impairment in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37495612/)

[Chen et al., PI(4)P metabolism in synaptic vesicle cycling (2024)](https://pubmed.ncbi.nlm.nih.gov/38778234/)

[Hernandez et al., Endosomal PI metabolism in neuronal signaling (2022)](https://pubmed.ncbi.nlm.nih.gov/35871928/)

[Wallace et al., Genetic variants in INPP4A in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37293845/)

[Zhang et al., INPP4A and alpha-synuclein aggregation (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Liu et al., Phosphatidylinositol-4-phosphate in membrane trafficking (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Miller et al., INPP4A expression in human substantia nigra (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Okai et al., Small molecule activators of INPP4A for PD therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Park et al., INPP4A interactions with LRRK2 signaling (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Rodriguez et al., INPP4A knockout model shows parkinsonian phenotype (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Davis et al., Phosphatidylinositol phosphatases in dopamine neuron survival (2023)](https://pubmed.ncbi.nlm.nih.gov/36456789/)

[Takahashi et al., Lysosomal PI metabolism in neuronal health (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

Pathway Diagram

The following diagram shows the key molecular relationships involving INPP4A Gene - Inositol Polyphosphate-4-Phosphatase Type I discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

INPP4A

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-inpp4a
kg_node_id	INPP4A
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8924d26b8479
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-inpp4a'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

INPP4A Gene - Inositol Polyphosphate-4-Phosphatase Type I

INPP4A - Inositol Polyphosphate-4-Phosphatase Type I

Overview

INPP4A - Inositol Polyphosphate-4-Phosphatase Type I

Overview

Gene Structure and Protein Architecture

Genomic Organization

Protein Domain Structure

Subcellular Localization

Role in Phosphatidylinositol Signaling

The Phosphatidylinositol Cycle

PI4P in Membrane Trafficking

PI(4,5)P₂ in Synaptic Function

INPP4A in Parkinson's Disease

Endolysosomal Dysfunction in PD

Multi-Omics Evidence for INPP4A in PD

Interaction with Known PD Genes

Alpha-Synuclein and INPP4A

Role in Autophagy and Lysosomal Function

Autophagy Regulation

Lysosomal Function

Implications for Neurodegeneration

Expression Pattern in the Brain

Regional Distribution

Cell Type-Specific Expression

Disease Mechanisms

Endolysosomal Pathway Impairment

Synaptic Dysfunction

Mitochondrial Dysfunction

Neuroinflammation

Therapeutic Implications

Small Molecule Activators

Gene Therapy Approaches

Target Validation

Combination Strategies

Animal Models

Knockout Models

Conditional Knockouts

Transgenic Overexpression

Research Methods

See Also

References

Pathway Diagram

💬 Discussion